Microneedles(MNs)are a prospective system in cancer immunotherapy to overcome barriers regarding proper antigen delivery and presentation.This study aims at identifying the potential of MNs for the delivery of Peptide...Microneedles(MNs)are a prospective system in cancer immunotherapy to overcome barriers regarding proper antigen delivery and presentation.This study aims at identifying the potential of MNs for the delivery of Peptide-coated Conditionally Replicating Adenoviruses(PeptiCRAd),whereby peptides enhance the immunogenic properties of adenoviruses presenting tumor associated antigens.The combination of PeptiCRAd with MNs containing polyvinylpyrrolidone and sucrose was tested for the preservation of structure,induction of immune response,and tumor eradication.The findings indicated that MN-delivered PeptiCRAd was effective in peptide presentation in vivo,leading to complete tumor rejection when mice were pre-vaccinated.A rise in the cDC1 population in the lymph nodes of the MN treated mice led to an increase in the effector memory T cells in the body.Thus,the results of this study demonstrate that the combination of MN technology with PeptiCRAd may provide a safer,more tolerable,and efficient approach to cancer immunotherapy,potentially translatable to other therapeutic applications.展开更多
基金support from the Research Council Finland(grant No.331151,HAS)UMCG Research Funds(HAS)+6 种基金the Finnish Cultural Foundation(CD)provided by the European Research Council(ERC)under the Horizon 2020 framework(grant No.681219,VC)the Magnus Ehrnrooth Foundation(project No.4706235,VC)the Jane and Aatos Erkko Foundation(project No.4705796,VC)the Finnish Cancer Foundation(project No.4706116,VC)the Helsinki Institute of Life Science(HiLIFE)(project No.797011004,VC)the Digital Precision Cancer Medicine Flagship iCAN(VC),and the GeneCellNano Flagship(VC).
文摘Microneedles(MNs)are a prospective system in cancer immunotherapy to overcome barriers regarding proper antigen delivery and presentation.This study aims at identifying the potential of MNs for the delivery of Peptide-coated Conditionally Replicating Adenoviruses(PeptiCRAd),whereby peptides enhance the immunogenic properties of adenoviruses presenting tumor associated antigens.The combination of PeptiCRAd with MNs containing polyvinylpyrrolidone and sucrose was tested for the preservation of structure,induction of immune response,and tumor eradication.The findings indicated that MN-delivered PeptiCRAd was effective in peptide presentation in vivo,leading to complete tumor rejection when mice were pre-vaccinated.A rise in the cDC1 population in the lymph nodes of the MN treated mice led to an increase in the effector memory T cells in the body.Thus,the results of this study demonstrate that the combination of MN technology with PeptiCRAd may provide a safer,more tolerable,and efficient approach to cancer immunotherapy,potentially translatable to other therapeutic applications.
